Endo International plc
Glandore Business Centres
No. 33 Fitzwilliam Square
Dublin 2
Tel: 353-1-669-8559 or 800-462-3636
Fax: 800-329-3636
Website: http://www.endo.com/
312 articles about Endo International plc
-
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting
5/5/2022
Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women.
-
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
5/2/2022
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc.
-
Endo to Announce First-Quarter 2022 Financial Results
4/12/2022
Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open.
-
Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials
3/28/2022
Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
-
Endo Reports Fourth-quarter And Full-Year 2021 Financial Results
2/28/2022
Endo International plc reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.
-
Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles
2/7/2022
Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping VASOSTRICT®, vasopressin injection, USP, in ready-to-use 100 mL pre-mix bottles.
-
Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results
1/25/2022
Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open.
-
Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism
1/13/2022
Endo International plc (NASDAQ:ENDP) announced today the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of AVEED® (testosterone undecanoate) in hypogonadal males.
-
Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
1/11/2022
Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18 , 2022.
-
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
1/4/2022
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Merz's CUVPOSA® 1 mg/5 mL oral solution in the U.S., following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
-
Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference
1/4/2022
Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST.
-
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada
12/23/2021
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada.
-
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting
11/22/2021
Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes) were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS).
-
Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection
11/18/2021
Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.
-
Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care
11/8/2021
Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT ® , vasopressin injection, USP, vial presentations to healthcare providers through Premier's Premier ProRx ® program
-
Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance
11/4/2021
Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021.
-
Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting
10/22/2021
Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.
-
Endo to Announce Third Quarter 2021 Financial Results
10/5/2021
Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open.
-
Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting
9/30/2021
Endo International plc (NASDAQ: ENDP) today announced results from the first two rounds of Delphi research exploring the expert positions of hand surgeons on the appropriate treatment of Dupuytren's disease (DD) with collagenase clostridium histolyticum (CCH) in patients with varying degrees of disease severity and functional impairment.
-
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
8/31/2021
Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc.